Document Detail

Immunotherapy with interleukin 2 after ABMT in AML.
MedLine Citation:
PMID:  8504274     Owner:  NLM     Status:  MEDLINE    
Myeloablative chemo (+/- radio) therapy and rescue with ABMT has been used as final consolidation therapy in 18 patients with AML in first remission. In seven (6 autologous, 1 syngeneic) marrow reinfusion was followed by iv IL-2. One patient, who commenced IL-2 4 days after BMT, died from pulmonary oedema due to the capillary leak syndrome. Thereafter, treatment with IL-2 was delayed until the platelet count reached 30 x 10(9)/l. All patients developed reversible hypotension (treated with infusion of colloid), but treatment was otherwise well tolerated. With 21-58 months (median 32 months) from the time of ABMT there has been one relapse (actuarial risk 17%, 95% confidence intervals (CI) 3-31%). The disease-free survival is 71% (95% CI 38-100%). Eleven patients with comparable remission induction and consolidation therapy, and an identical interval between diagnosis and ABMT (5-11 months, median 6 months) received an autograft without immunotherapy. With 24-45 months (median 29 months) follow-up the actuarial disease-free survival is 36% (95% CI 8-64%), the actuarial relapse risk is 54% (95% CI 18-90%). We conclude that immunotherapy given after ABMT to patients with AML in first remission when the platelet count exceeds 30 x 10(9)/l is safe and may induce an immunological environment which results in the elimination of residual leukaemia.
M D Hamon; H G Prentice; D J Gottlieb; I D Macdonald; J M Cunningham; O P Smith; M Gilmore; L Gandhi; C Collis
Related Documents :
12068794 - Combined therapy in advanced stages (iii and iv) of follicular lymphoma increases the p...
19450284 - Socioeconomic status and survival of cirrhosis patients: a danish nationwide cohort study.
15170154 - Adriamycin and cis-platinum as first-line treatment in unresectable locally advanced or...
15665394 - Matrix metalloproteinase-2, squamous cell carcinoma antigen, and tissue polypeptide-spe...
12366734 - Effect of vagal nerve stimulation on interictal epileptiform discharges: a scalp eeg st...
2454904 - Heat, drugs, and radiation given in combination is palliative for unresectable esophage...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Bone marrow transplantation     Volume:  11     ISSN:  0268-3369     ISO Abbreviation:  Bone Marrow Transplant.     Publication Date:  1993 May 
Date Detail:
Created Date:  1993-07-08     Completed Date:  1993-07-08     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8702459     Medline TA:  Bone Marrow Transplant     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  399-401     Citation Subset:  IM    
Department of Haematology, Royal Free Hospital and School of Medicine, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bone Marrow Transplantation*
Combined Modality Therapy
Interleukin-2 / therapeutic use*
Leukemia, Myeloid, Acute / surgery,  therapy*
Middle Aged
Remission Induction
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of DMSO exposure without cryopreservation on hematopoietic progenitor cells.
Next Document:  Pentamidine aerosol for prophylaxis of Pneumocystis carinii pneumonia after BMT.